StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Oncotelic Therapeutics's enterprise value was $7.15M on Oct 19, 2026, against $41.33M a year earlier. Over the last 5 years it ranged from $7.15M to $93.82M, with a median of $19.09M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Oct 19, 2026$7.15M-78.8%
2025Dec 31, 2025$33.73M+114.0%
2024Dec 31, 2024$15.77M-5.4%
2023Dec 29, 2023$16.66M-12.8%
2022Dec 30, 2022$19.10M-70.2%
2021Dec 31, 2021$63.98M+229.8%
2020Dec 31, 2020$19.40M+36.9%
2019Dec 31, 2019$14.17M–
2018Dec 31, 2018-$455.53K–
2017Dec 29, 2017-$1.18M–
2016Dec 30, 2016-$14.54M–
2015Dec 31, 2015-$26.58M–
2014Dec 31, 2014-$26.83M–
2013Dec 31, 2013-$7.40M–
2012Dec 31, 2012-$4.70M–
2011Dec 30, 2011-$9.99M–

More Oncotelic Therapeutics figures

See a number that looks wrong?